T cell receptor recognizing Myelin Basic Protein 82-100 epitope (TCR-MBP(82-100))

The T cell receptor recognizing the Myelin Basic Protein (MBP) 82-100 epitope is a specialized immune receptor primarily involved in the autoimmune pathogenesis of Multiple Sclerosis (MS) (Source: PubMed, PMID: 1697878). This TCR specifically identifies the 82-100 amino acid sequence of MBP, a major component of the myelin sheath, when it is presented by the HLA-DRB1*15:01 (HLA-DR2) MHC class II molecule (Source: Nature, 1990). In MS patients, the activation of T cells bearing this TCR triggers a pro-inflammatory cascade that leads to the destruction of myelin in the central nervous system (Source: Journal of Clinical Investigation). Because of its central role in neuroinflammation, this TCR is a primary target for antigen-specific immunotherapies designed to restore immune tolerance (Source: NIH). Therapeutic approaches include the use of altered peptide ligands (APLs) like NBI-5788 that modify the TCR signal to induce anergy rather than activation, as well as TCR-based vaccines like NeuroVax that target the specific variable regions of the receptor (Source: Nature Medicine; Neurology). Monitoring the frequency and activation state of these MBP-specific T cells serves as a vital biomarker for assessing disease progression and the efficacy of tolerogenic treatments (Source: PubMed).

Other names

MBP-specific T-cell receptorAnti-MBP 82-100 TCRMyelin basic protein (82-100)-specific T-cell receptorMBP82-100-reactive TCR

Induction of immune tolerance or anergy through altered peptide ligands or TCR-specific vaccination to suppress autoreactive T cell responses.